Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
130.76
+3.76 (+2.96%)
Streaming Delayed Price
Updated: 1:26 PM EDT, Apr 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
82
83
Next >
Understanding Merck & Co's Position In Pharmaceuticals Industry Compared To Competitors
April 08, 2024
Via
Benzinga
2 Dividend Stocks to Buy and Hold Forever
April 08, 2024
These dividends are about as safe as they come.
Via
The Motley Fool
Down 75%. Is Agenus Stock a Buy on the Dip?
April 08, 2024
Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.
Via
The Motley Fool
The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024
April 07, 2024
Our economy is on the up and up, and investing is a must. Let's review the most undervalued S&P 500 stocks to buy in April.
Via
InvestorPlace
Topics
Economy
Stocks
Exposures
Economy
US Equities
10 Health Care Stocks Whale Activity In Today's Session
April 04, 2024
Via
Benzinga
Cancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing Data
April 04, 2024
eFFECTOR Therapeutics unveils Phase 2 KICKSTART trial results for tomivosertib with Keytruda in NSCLC patients. Tomivosertib shows modest activity, but no clear path forward. Zotatifin emerges as a...
Via
Benzinga
Market Whales and Their Recent Bets on MRK Options
April 03, 2024
Via
Benzinga
Expert Ratings For Merck & Co
April 01, 2024
Via
Benzinga
Looking At Merck & Co's Recent Unusual Options Activity
March 28, 2024
Via
Benzinga
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
April 04, 2024
From
Merck & Co., Inc.
Via
Business Wire
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
April 03, 2024
From
Daiichi Sankyo
Via
Business Wire
Forget Shopify: This Stock Has Made Far More Millionaires
April 03, 2024
It's a reliable winner with plenty more room to run.
Via
The Motley Fool
Smart Money Is Betting Big In MRK Options
March 25, 2024
Via
Benzinga
Russell 2000 Index Best And Worst Performing Stocks Of 2024
April 02, 2024
The Russell 2000 index continued to underperform the Dow Jones and Nasdaq 100 indices in the first quarter of 2024.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
April 01, 2024
From
Merck & Co., Inc.
Via
Business Wire
Which Blue Chip Led The Dow Jones Industrials In Q1?
March 29, 2024
Disney and Caterpillar led gains among Dow Jones stocks in the first quarter. Boeing posted the largest decline.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
3 Strong Buy Healthcare Stocks to Add to Your Q2 Must-Watch List
March 29, 2024
In an aging world, strong buy healthcare stocks like UNH, ABT, and MRK shine with dividends, innovation, and market growth.
Via
InvestorPlace
Stock Market Rally Shows Breadth As Leaders Take A Breath: Weekly Review
March 28, 2024
The stock market rally showed breadth, with small caps leading the way to a 24-month high. Growth leaders like Nvidia took a break.
Via
Investor's Business Daily
Japan Index Falls While Asia And Europe Markets Rise, And Gold Exceeds $2,220 - Global Markets Today While US Slept
March 28, 2024
Via
Benzinga
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
March 28, 2024
From
Merck & Co., Inc.
Via
Business Wire
The Reserve Bank Of South Africa Kept The Rate At 8.25%
March 28, 2024
The Reserve Bank of South Africa unanimously decided to keep the key repo rate at 8.25%, marking the fifth consecutive meeting at 2009 levels, as expected.
Via
Talk Markets
Merck Stock Soars On FDA Approval for Winrevair: Technical Analysis And Market Outlook
March 27, 2024
Merck acquired sotatercept via its $11 billion acquisition of Acceleron Pharma, underscoring a commitment to advancing innovative therapies.
Via
Benzinga
Exposures
Product Safety
The Most Important Catalyst For Merck's Stock In 2024 Could Be Sotatercept Launch, Analyst Says
March 27, 2024
Cantor Fitzgerald notes Merck's robust stock performance, up 15% YTD vs S&P 500's 10%.Potential peak sales projections ranging from $1 billion to $8 billion. Merck targets 40,000 potential patients.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday
March 27, 2024
U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Merck's $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease
March 27, 2024
FDA approves Merck's Winrevair for PAH treatment. First-in-class therapy to enhance exercise capacity, improve WHO FC, and reduce clinical worsening. Available in select U.S. pharmacies by April....
Via
Benzinga
Exposures
Product Safety
US Stocks Set For Rebound, Aim To Snap 3-Session Slump And Close Quarter Strong: Analyst Foresees Robust April Ahead
March 27, 2024
Bargain hunters may flock to the market on Wednesday following three consecutive sessions of losses.
Via
Benzinga
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
March 26, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck's Cardiovascular 'Renaissance' Is Here With The First Approval Of A $10 Billion Franchise
March 26, 2024
The FDA signed off on Winrevair, a treatment for pulmonary arterial hypertension.
Via
Investor's Business Daily
Exposures
Product Safety
Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment
March 26, 2024
Stifel covers Summit Therapeutics, highlighting ivonescimab's promise in phase 3 lung cancer trials, potential market expansion worth billions, and a buy rating with $8 target. Updates from Akeso in...
Via
Benzinga
Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer
March 24, 2024
Novo Nordisk and Nvidia have teamed up to develop supercomputers, aiming to accelerate drug discovery development using advanced AI technologies.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
< Previous
1
2
3
4
5
6
7
8
9
...
82
83
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.